Evidence map›Paper›PMID 42771133›Full record

ReviewHormones (Athens, Greece)2026

Epigenetic modifications in type 2 diabetes mellitus.

Marina Spaho, Fotios Karytis, Stavros P Papadakos, Antonios Chatzigeorgiou

Abstract readReview
PubMed Publisher
In one paragraph

Review in Hormones (Athens, Greece), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Marina SpahoFourth Department of Internal Medicine, Hippokration General Hospital, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Fotios KarytisDepartment of Physiology, Medical School, National and Kapodistrian University of Athens, M. Asias 75, Goudi, Athens, 11527, Greece.
Stavros P Papadakos *Department of Physiology, Medical School, National and Kapodistrian University of Athens, M. Asias 75, Goudi, Athens, 11527, Greece. stavrospapadakos@gmail.com.
Antonios Chatzigeorgiou *Department of Physiology, Medical School, National and Kapodistrian University of Athens, M. Asias 75, Goudi, Athens, 11527, Greece. achatzig@med.uoa.gr.ORCID http://orcid.org/0000-0002-7039-4223

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 2 diabetes mellitus (T2DM) develops through the interplay of insulin resistance and progressive beta-cell dysfunction. Beyond genetic predisposition, epigenetic regulation provides a mechanistic link between environmental exposures (e.g., overnutrition, physical inactivity, inflammation) and durable changes in gene expression in pancreatic islets and insulin-sensitive tissues (skeletal muscle, adipose tissue, and liver). Accordingly, this review aims to synthesize current evidence on the epigenetic mechanisms underlying T2DM and its complications, with a particular focus on epigenetically targeted therapeutic strategies. We summarize major epigenetic processes, including DNA and RNA methylation, histone post-translational modifications, and non-coding RNAs, and discuss how these alterations remodel chromatin and transcriptional programs under metabolic stress. A key concept is "metabolic memory," whereby transient hyperglycemia or lipotoxicity can induce persistent epigenetic signatures that sustain dysfunctional cellular phenotypes, partly shaped by mitochondrial metabolism and Krebs cycle intermediates regulating chromatin-modifying enzymes. Importantly, several epigenetic alterations demonstrate partial reversibility following lifestyle modification, metabolic surgery, or pharmacological intervention (e.g., DNA methyltransferase inhibition), underscoring their therapeutic relevance. Finally, we address translational challenges, including limited access to human tissues and inadequate modeling of chronic metabolic stress, which currently constrain clinical exploitation of epigenetic targets in T2DM.

Indexed as

Beta-cell dysfunctionEpigeneticsInsulin resistanceMetabolic memoryType 2 diabetes mellitus

Identifiers

PMID42771133

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.